BridgeMD
Compares treatment options for Rhegmatogenous Retinal Detachment
Official title Treatment of Retinal Detachment in People Who Have Not Had Cataract Surgery With Vitrectomy vs Vitrectomy and Cataract Removal
ClinicalTrials.gov ID: NCT06997874
What this study is testing
- What it's testing
- Background and study aims The retina is the layer at the back of the eye that allows us to see. Sometimes, it can detach from the wall of the eye, causing a condition called rhegmatogenous retinal detachment (RRD), which leads to vision loss and requires surgery.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Adults ≥50 years of age
- Non-highly myopic (\< -6 diopters; ≤26.5 mm axial length) phakic RRD
- Naive to previous vitreoretinal surgery
- Pars plana vitrectomy is planned to repair their RRD
You likely can't join if
- Presence of a "formed/established cataract." A "formed/established cataract" is defined as a cataract that, based on the Age-Related Eye Disease...
- Pseudophakia or aphakia
- High myopia (≥ -6 diopters; \>26.5 mm axial length)
- Giant retinal tear (i.e. presence of one or more retinal tears of \>3 clock hours in size)
- Retinal dialysis
- Inclusion in an investigational drug study
See the full eligibility criteria
- Adults ≥50 years of age
- Non-highly myopic (\< -6 diopters; ≤26.5 mm axial length) phakic RRD
- Naive to previous vitreoretinal surgery
- Pars plana vitrectomy is planned to repair their RRD
- Presence of a "formed/established cataract." A "formed/established cataract" is defined as a cataract that, based on the Age-Related Eye Disease Study (AREDS) Research Group, is graded as nuclear sclerosis of \>3 and/or...
- Pseudophakia or aphakia
- High myopia (≥ -6 diopters; \>26.5 mm axial length)
- Giant retinal tear (i.e. presence of one or more retinal tears of \>3 clock hours in size)
- Retinal dialysis
- Inclusion in an investigational drug study
- Declined consent for participation
The study team makes the final eligibility decision.
Where it's taking place
- Aylesbury, United Kingdom
- Belfast, United Kingdom
- Birmingham, United Kingdom
- Bradford, United Kingdom
- Bristol, United Kingdom
- Darlington, United Kingdom
- Edinburgh, United Kingdom
- Glasgow, United Kingdom
- Hull, United Kingdom
- Leeds, United Kingdom
- Leicester, United Kingdom
- Liverpool, United Kingdom
- London, United Kingdom
- Manchester, United Kingdom
- Metropolitan Borough of Wirral, United Kingdom
- Middlesbrough, United Kingdom
- Newcastle upon Tyne, United Kingdom
- Norwich, United Kingdom
- Nottingham, United Kingdom
- Oxford, United Kingdom
+ 7 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Aylesbury, United Kingdom; Belfast, United Kingdom; Birmingham, United Kingdom; Bradford, United Kingdom; Bristol, United Kingdom; Darlington, United Kingdom and 21 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.